

Payment Policy | Laser Treatment for Onychomycosis



EFFECTIVE DATE: 02|07|2017

POLICY LAST UPDATED: 02|06|2020

OVERVIEW

Onychomycosis is a common fungal infection of the nail. Currently available treatments for onychomycosis, including systemic and topical antifungal medications, have relatively low efficacy and require a long course of treatment. Laser systems are proposed as another treatment option.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

Laser treatment of onychomycosis is considered not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial

Laser treatment of onychomycosis is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessity benefits/coverage.

BACKGROUND

Onychomycosis is a common chronic fungal infection of the nail. It is estimated to cause up to 50% of all nail disease and 33% of cutaneous fungal infections. The condition can affect toenails or fingernails but is more frequently found in toenails. Primary infectious agents include dermatophytes (eg, *Trichophyton* species), yeasts (eg, *Candida albicans*), and nondermatophytic molds. In temperate Western countries, infections are generally caused by dermatophytes.

Aging is the most common risk factor for onychomycosis, most likely due to decreased blood circulation, longer exposure to fungi, and slower nail growth. In addition, various medical conditions increase the risk of comorbid onychomycosis. They include diabetes, obesity, peripheral vascular disease, immunosuppression, and HIV infection. In certain populations, onychomycosis may lead to additional health problems. Although there is limited evidence of a causal link between onychomycosis and diabetic foot ulcers, at least 1 prospective study with diabetic patients found onychomycosis to be an independent predictor of foot ulcer. Moreover, onychomycosis, especially more severe cases, may adversely impact quality of life. Patients with onychomycosis have reported pain, uncomfortable nail pressure, embarrassment, and discomfort wearing shoes.

The diagnosis of onychomycosis can be confirmed by potassium hydroxide preparation, culture, or histology. Treatments for onychomycosis include topical antifungals such as nail paints containing ciclopirox (ciclopiroxolamine) or amorolfine, and oral antifungals such as terbinafine and itraconazole. These generally

have low-to-moderate efficacy and a high relapse rate. Topical antifungals and some long-available oral medications (eg, griseofulvin) require a long course of treatment, which presents issues for patient compliance. Moreover, oral antifungal medications have been associated with adverse effects such as a risk of hepatotoxicity.

Several types of device-based therapies are under investigation for treatment of onychomycosis, including ultrasound, iontophoresis, photodynamic therapy, and laser systems. A potential advantage of lasers is that they have greater tissue penetration than antifungal medication and thus may be more effective at treating infection embedded within the nail. Another potential advantage is that laser treatments are provided in a clinical setting in only 1 or several sessions and, thus, requires less long-term patient compliance.

Several types of device-based therapies are under investigation for treatment of onychomycosis, including ultrasound, iontophoresis, photodynamic therapy, and laser systems. A potential advantage of lasers is that they have greater tissue penetration than antifungal medication and thus may be more effective at treating infection embedded within the nail. Another potential advantage is that laser treatments are provided in a clinical setting in only 1 or several sessions and, thus, requires less long-term patient compliance.

Laser treatment of onychomycosis uses the principle of selective photothermolysis. This is defined as the precise targeting of a tissue using a specific wavelength of light. The premise is that light is absorbed into the target area and heat generated by that energy is sufficient to damage the target area while sparing the surrounding area. The aim of laser treatment for onychomycosis is to heat the nail bed to temperatures required to disrupt fungal growth (approximately 40° -60° C) and at the same time avoid pain and necrosis to surrounding tissues.

For individuals who have onychomycosis who receive treatment with laser therapy, the evidence includes small randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, medication use, and treatment-related morbidity. Some of the available RCTs have reported improvements in clinical outcomes with laser treatment, but these trials have mixed results and methodologic limitations. Clinical and mycological outcomes sometimes differed in the trials, which may be due in part to lack of consistent blinding of outcome assessment. The published evidence to date does not permit determining whether laser treatment improves health outcomes in patients with onychomycosis. Additional well-designed, adequately powered, and well-conducted RCTs are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

CODING

There is no specific CPT code for this treatment. It would likely be reported using an unlisted CPT code such as 17999 (Unlisted procedure, skin, mucous membrane and subcutaneous tissue) or 96999.

RELATED POLICIES

Routine Foot Care and Nail Debridement

PUBLISHED

Provider Update, April 2020

Provider Update, July 2019

Provider Update, April 2018

Provider Update, April 2017

REFERENCES:

1. Rodgers P, Bassler M. Treating onychomycosis. *Am Fam Physician*. Feb 15 2001;63(4):663-672, 677-668. PMID 11237081
2. Boyko EJ, Ahroni JH, Cohen V, et al. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. *Diabetes Care*. Jun 2006;29(6):1202-1207. PMID 16731996
3. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. *J Am Acad Dermatol*. May

1998;38(5 Pt 1):702-704. PMID 9591814

4. Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. *Am J Clin Dermatol*. Jan-Feb 2000;1(1):19-26. PMID 11702301

5. Gupta A, Simpson F. Device-based therapies for onychomycosis treatment. *Skin Therapy Lett*. Oct 2012;17(9):4-9. PMID 23032936

6. Bristow IR. The effectiveness of lasers in the treatment of onychomycosis: a systematic review. *J Foot Ankle Res*. Aug 2014;7:34. PMID 25104974

7. Karsai S, Jager M, Oesterhelt A, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. *J Eur Acad Dermatol Venereol*. Jan 2017;31(1):175-180. PMID 275210286. Bristow IR. The effectiveness of lasers in the treatment of onychomycosis: a systematic review. *J Foot Ankle Res*. 2014;7:34. PMID 25104974

8. Kim TI, Shin MK, Jeong KH, et al. A randomised comparative study of 1064 nm Neodymium-doped yttrium aluminium garnet (Nd:YAG) laser and topical antifungal treatment of onychomycosis. *Mycoses*. Jul 12 2016. PMID 27402466

9. El-Tatawy RA, Abd El-Naby NM, El-Hawary EE, et al. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. *J Dermatolog Treat*. Feb 11 2015;1-4. PMID 25669435

10. Xu Y, Miao X, Zhou B, et al. Combined oral terbinafine and long-pulsed 1,064-nm Nd: YAG laser treatment is more effective for onychomycosis than either treatment alone. *Dermatol Surg*. Nov 2014;40(11):1201-1207. PMID 25322165

11. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. *J Am Podiatr Med Assoc*. May-Jun 2010;100(3):166-177. PMID 20479446

12. Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days. *J Am Podiatr Med Assoc*. Mar-Apr 2012;102(2):169-171. PMID 22461276

13. Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. *Br J Dermatol*. Nov 2014;171(5):937-958. PMID 25409999

Kim TI, Shin MK, Jeong KH, et al. A randomised comparative study of 1064 nm Neodymium-doped yttrium aluminium garnet (Nd:YAG) laser and topical antifungal treatment of onychomycosis. *Mycoses*. Jul 12 2016;59(12):803-810. PMID 27402466

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

